Profile data is unavailable for this security.
About the company
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
- Revenue in USD (TTM)0.00
- Net income in USD-7.82m
- Incorporated2024
- Employees32.00
- LocationGrace Therapeutics, Inc103 Carnegie Center, Suite 300PRINCETON 08540United StatesUSA
- Phone+1 (609) 322-1602
- Fax+1 (302) 636-5454
- Websitehttps://www.gracetx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instil Bio Inc | 0.00 | -75.08m | 52.15m | 14.00 | -- | 0.4331 | -- | -- | -11.39 | -11.39 | 0.00 | 17.76 | 0.00 | -- | -- | 0.00 | -31.00 | -34.59 | -32.06 | -36.59 | -- | -- | -- | -469,515.20 | -- | -19.23 | 0.4127 | -- | -- | -- | 52.50 | -- | 116.55 | -- |
| Cingulate Inc | 0.00 | -22.06m | 52.52m | 13.00 | -- | 11.74 | -- | -- | -5.35 | -5.35 | 0.00 | 0.5811 | 0.00 | -- | -- | 0.00 | -183.12 | -157.80 | -264.65 | -303.36 | -- | -- | -- | -- | -- | -19.54 | 0.4783 | -- | -- | -- | 33.95 | -- | -26.92 | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 52.53m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 242.00k | -38.06m | 52.82m | 2.00 | -- | -- | -- | 218.28 | -2.32 | -2.32 | 0.0141 | -0.9304 | 0.0249 | -- | -- | -- | -391.21 | -210.73 | -- | -603.16 | 59.92 | -- | -15,727.69 | -- | -- | -- | -- | -- | -- | -- | 16.69 | -- | -- | -- |
| Tscan Therapeutics Inc | 8.42m | -142.60m | 56.55m | 146.00 | -- | 0.3927 | -- | 6.71 | -1.12 | -1.12 | 0.066 | 2.54 | 0.0276 | -- | -- | 43,417.53 | -46.73 | -38.91 | -51.63 | -43.93 | -- | -- | -1,692.96 | -735.59 | -- | -- | 0.1837 | -- | -86.62 | -- | -42.91 | -- | 25.13 | -- |
| Grace Therapeutics, Inc | 0.00 | -7.82m | 56.79m | 32.00 | -- | 0.8254 | -- | -- | -0.5851 | -0.5851 | 0.00 | 4.45 | 0.00 | -- | -- | -- | -11.85 | -24.13 | -12.22 | -25.07 | -- | -- | -- | -48,136.22 | -- | -- | 0.00 | -- | -- | -- | 25.56 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -13.50m | 58.01m | -- | -- | -- | -- | -- | -0.3697 | -0.3697 | 0.00 | -0.2605 | 0.00 | -- | -- | -- | -371.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 80.64k | -14.64m | 58.60m | 12.00 | -- | -- | -- | 726.63 | -12.28 | -12.28 | 0.0562 | -3.63 | 0.0083 | -- | 0.0571 | -- | -149.76 | -64.49 | -- | -99.77 | -- | -- | -18,159.65 | -573.31 | -- | -- | -- | -- | -95.09 | 11.58 | 22.69 | -- | -- | -- |
| Metagenomi Therapeutics Inc | 30.91m | -88.74m | 58.93m | 124.00 | -- | 0.3303 | -- | 1.91 | -2.39 | -2.39 | 0.8308 | 4.75 | 0.102 | -- | 39.91 | 153,034.70 | -29.27 | -- | -33.42 | -- | -- | -- | -287.06 | -- | -- | -- | 0.00 | -- | 16.84 | -- | -14.36 | -- | -- | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.67m | 59.54m | 0.00 | -- | -- | -- | -- | -0.1455 | -0.1455 | 0.00 | -0.1168 | 0.00 | -- | -- | -- | -5,576.42 | -14,417.91 | -- | -- | -- | -- | -- | -- | -- | -684.26 | -- | -- | -- | -- | -106.65 | -- | -- | -- |
| Shanrong Biotechnology Corp | 1.32m | -5.08m | 60.02m | 3.00 | -- | -- | -- | 45.31 | -15.40 | -15.40 | 4.10 | -11.40 | 4.45 | -- | 11.81 | 441,576.70 | -1,705.30 | -- | -- | -- | -- | -- | -383.32 | -- | 0.0315 | -16.22 | -- | -- | 91.44 | -- | -86.62 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -82.71m | 62.26m | 63.00 | -- | 0.5124 | -- | -- | -1.58 | -1.58 | 0.00 | 2.28 | 0.00 | -- | -- | 0.00 | -46.29 | -21.46 | -49.90 | -22.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.87 | -- | 43.14 | -- |
| Beyondspring Inc | 0.00 | -7.83m | 62.46m | 40.00 | -- | -- | -- | -- | -0.1942 | -0.0148 | 0.00 | -0.788 | -- | -- | -- | 0.00 | -- | -61.84 | -- | -81.30 | -- | -- | -- | -6,633.90 | -- | -- | -- | -- | -- | -- | 35.26 | -- | 123.69 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 30 Sep 2025 | 1.18m | 7.61% |
| AIGH Capital Management LLCas of 31 Dec 2025 | 907.22k | 5.86% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 494.70k | 3.20% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 415.23k | 2.68% |
| Adar1 Capital Management LLCas of 30 Sep 2025 | 350.45k | 2.27% |
| Stonepine Capital Management LLCas of 30 Sep 2025 | 211.01k | 1.36% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 84.56k | 0.55% |
| Citadel Securities LLCas of 30 Sep 2025 | 27.27k | 0.18% |
| Millington Financial Advisors LLCas of 30 Sep 2025 | 20.00k | 0.13% |
| GSA Capital Partners LLPas of 31 Dec 2025 | 13.77k | 0.09% |
